The Experts below are selected from a list of 9615 Experts worldwide ranked by ideXlab platform
David E Gyorki - One of the best experts on this subject based on the ideXlab platform.
-
post operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre operative treatment and elective indication
Journal of Surgical Oncology, 2015Co-Authors: Mike He, Jane Lovell, Bee Ling Ng, John Spillane, David Speakman, Michael A Henderson, Mark Shackleton, David E GyorkiAbstract:INTRODUCTION: Metastasectomy can provide durable disease control for selected patients with metastatic melanoma. Vemurafenib is a BRAF kinase inhibitor which has demonstrated significant improvement in disease-specific survival in patients with metastatic melanoma with a BRAF Gene mutation. This study examined the efficacy and safety of metastasectomy during treatment with vemurafenib. METHODS: A retrospective review was performed of all patients receiving vemurafenib at Peter MacCallum Cancer Centre. Patient records were reviewed to identify patients undergoing surgery within 30 days of vemurafenib therapy. Descriptive statistics and survival analysis were performed. RESULTS: Nineteen patients underwent 21 metastasectomies including craniotomy (57%), spinal decompression (14%), small bowel resection (14%), lung resection (9.5%) and neck dissection (4.5%). Indications for surgery were: an isolated residual focus of disease (n = 2); isolated progressive disease in the setting of stability elsewhere (n = 9); and symptomatic disease (n = 8). Grade 2 or higher surgical complications occurred in 19% of cases and there was one peri-operative death. Median post-operative survival was seven months. There was a trend toward improved post-operative survival for patients with longer duration of vemurafenib therapy (P = 0.04) and for those undergoing elective surgery (P = 0.07). CONCLUSION: Resection of oligometastatic disease during BRAF-targeted therapy is safe. Selected patients have durable post-operative disease control.
-
post operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre operative treatment and elective indication
Journal of Surgical Oncology, 2015Co-Authors: Jane Lovell, John Spillane, David Speakman, Michael A Henderson, Mark Shackleton, David E GyorkiAbstract:Introduction Metastasectomy can provide durable disease control for selected patients with metastatic melanoma. Vemurafenib is a BRAF kinase inhibitor which has demonstrated significant improvement in disease-specific survival in patients with metastatic melanoma with a BRAF Gene mutation. This study examined the efficacy and safety of metastasectomy during treatment with vemurafenib. Methods A retrospective review was performed of all patients receiving vemurafenib at Peter MacCallum Cancer Centre. Patient records were reviewed to identify patients undergoing surgery within 30 days of vemurafenib therapy. Descriptive statistics and survival analysis were performed. Results Nineteen patients underwent 21 metastasectomies including craniotomy (57%), spinal decompression (14%), small bowel resection (14%), lung resection (9.5%) and neck dissection (4.5%). Indications for surgery were: an isolated residual focus of disease (n = 2); isolated progressive disease in the setting of stability elsewhere (n = 9); and symptomatic disease (n = 8). Grade 2 or higher surgical complications occurred in 19% of cases and there was one peri-operative death. Median post-operative survival was seven months. There was a trend toward improved post-operative survival for patients with longer duration of vemurafenib therapy (P = 0.04) and for those undergoing elective surgery (P = 0.07). Conclusion Resection of oligometastatic disease during BRAF-targeted therapy is safe. Selected patients have durable post-operative disease control. J. Surg. Oncol. 2015 111:980–984. © 2015 Wiley Periodicals, Inc.
Mark Shackleton - One of the best experts on this subject based on the ideXlab platform.
-
post operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre operative treatment and elective indication
Journal of Surgical Oncology, 2015Co-Authors: Mike He, Jane Lovell, Bee Ling Ng, John Spillane, David Speakman, Michael A Henderson, Mark Shackleton, David E GyorkiAbstract:INTRODUCTION: Metastasectomy can provide durable disease control for selected patients with metastatic melanoma. Vemurafenib is a BRAF kinase inhibitor which has demonstrated significant improvement in disease-specific survival in patients with metastatic melanoma with a BRAF Gene mutation. This study examined the efficacy and safety of metastasectomy during treatment with vemurafenib. METHODS: A retrospective review was performed of all patients receiving vemurafenib at Peter MacCallum Cancer Centre. Patient records were reviewed to identify patients undergoing surgery within 30 days of vemurafenib therapy. Descriptive statistics and survival analysis were performed. RESULTS: Nineteen patients underwent 21 metastasectomies including craniotomy (57%), spinal decompression (14%), small bowel resection (14%), lung resection (9.5%) and neck dissection (4.5%). Indications for surgery were: an isolated residual focus of disease (n = 2); isolated progressive disease in the setting of stability elsewhere (n = 9); and symptomatic disease (n = 8). Grade 2 or higher surgical complications occurred in 19% of cases and there was one peri-operative death. Median post-operative survival was seven months. There was a trend toward improved post-operative survival for patients with longer duration of vemurafenib therapy (P = 0.04) and for those undergoing elective surgery (P = 0.07). CONCLUSION: Resection of oligometastatic disease during BRAF-targeted therapy is safe. Selected patients have durable post-operative disease control.
-
post operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre operative treatment and elective indication
Journal of Surgical Oncology, 2015Co-Authors: Jane Lovell, John Spillane, David Speakman, Michael A Henderson, Mark Shackleton, David E GyorkiAbstract:Introduction Metastasectomy can provide durable disease control for selected patients with metastatic melanoma. Vemurafenib is a BRAF kinase inhibitor which has demonstrated significant improvement in disease-specific survival in patients with metastatic melanoma with a BRAF Gene mutation. This study examined the efficacy and safety of metastasectomy during treatment with vemurafenib. Methods A retrospective review was performed of all patients receiving vemurafenib at Peter MacCallum Cancer Centre. Patient records were reviewed to identify patients undergoing surgery within 30 days of vemurafenib therapy. Descriptive statistics and survival analysis were performed. Results Nineteen patients underwent 21 metastasectomies including craniotomy (57%), spinal decompression (14%), small bowel resection (14%), lung resection (9.5%) and neck dissection (4.5%). Indications for surgery were: an isolated residual focus of disease (n = 2); isolated progressive disease in the setting of stability elsewhere (n = 9); and symptomatic disease (n = 8). Grade 2 or higher surgical complications occurred in 19% of cases and there was one peri-operative death. Median post-operative survival was seven months. There was a trend toward improved post-operative survival for patients with longer duration of vemurafenib therapy (P = 0.04) and for those undergoing elective surgery (P = 0.07). Conclusion Resection of oligometastatic disease during BRAF-targeted therapy is safe. Selected patients have durable post-operative disease control. J. Surg. Oncol. 2015 111:980–984. © 2015 Wiley Periodicals, Inc.
Michael A Henderson - One of the best experts on this subject based on the ideXlab platform.
-
post operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre operative treatment and elective indication
Journal of Surgical Oncology, 2015Co-Authors: Mike He, Jane Lovell, Bee Ling Ng, John Spillane, David Speakman, Michael A Henderson, Mark Shackleton, David E GyorkiAbstract:INTRODUCTION: Metastasectomy can provide durable disease control for selected patients with metastatic melanoma. Vemurafenib is a BRAF kinase inhibitor which has demonstrated significant improvement in disease-specific survival in patients with metastatic melanoma with a BRAF Gene mutation. This study examined the efficacy and safety of metastasectomy during treatment with vemurafenib. METHODS: A retrospective review was performed of all patients receiving vemurafenib at Peter MacCallum Cancer Centre. Patient records were reviewed to identify patients undergoing surgery within 30 days of vemurafenib therapy. Descriptive statistics and survival analysis were performed. RESULTS: Nineteen patients underwent 21 metastasectomies including craniotomy (57%), spinal decompression (14%), small bowel resection (14%), lung resection (9.5%) and neck dissection (4.5%). Indications for surgery were: an isolated residual focus of disease (n = 2); isolated progressive disease in the setting of stability elsewhere (n = 9); and symptomatic disease (n = 8). Grade 2 or higher surgical complications occurred in 19% of cases and there was one peri-operative death. Median post-operative survival was seven months. There was a trend toward improved post-operative survival for patients with longer duration of vemurafenib therapy (P = 0.04) and for those undergoing elective surgery (P = 0.07). CONCLUSION: Resection of oligometastatic disease during BRAF-targeted therapy is safe. Selected patients have durable post-operative disease control.
-
post operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre operative treatment and elective indication
Journal of Surgical Oncology, 2015Co-Authors: Jane Lovell, John Spillane, David Speakman, Michael A Henderson, Mark Shackleton, David E GyorkiAbstract:Introduction Metastasectomy can provide durable disease control for selected patients with metastatic melanoma. Vemurafenib is a BRAF kinase inhibitor which has demonstrated significant improvement in disease-specific survival in patients with metastatic melanoma with a BRAF Gene mutation. This study examined the efficacy and safety of metastasectomy during treatment with vemurafenib. Methods A retrospective review was performed of all patients receiving vemurafenib at Peter MacCallum Cancer Centre. Patient records were reviewed to identify patients undergoing surgery within 30 days of vemurafenib therapy. Descriptive statistics and survival analysis were performed. Results Nineteen patients underwent 21 metastasectomies including craniotomy (57%), spinal decompression (14%), small bowel resection (14%), lung resection (9.5%) and neck dissection (4.5%). Indications for surgery were: an isolated residual focus of disease (n = 2); isolated progressive disease in the setting of stability elsewhere (n = 9); and symptomatic disease (n = 8). Grade 2 or higher surgical complications occurred in 19% of cases and there was one peri-operative death. Median post-operative survival was seven months. There was a trend toward improved post-operative survival for patients with longer duration of vemurafenib therapy (P = 0.04) and for those undergoing elective surgery (P = 0.07). Conclusion Resection of oligometastatic disease during BRAF-targeted therapy is safe. Selected patients have durable post-operative disease control. J. Surg. Oncol. 2015 111:980–984. © 2015 Wiley Periodicals, Inc.
Cabrera Edgar Vladimir - One of the best experts on this subject based on the ideXlab platform.
-
Enfermedad de Erdheim-Chester: primer caso pediátrico reportado en Colombia
'Instituto Nacional de Salud (Colombia)', 2021Co-Authors: Salazar, Luis Carlos, Moreno Luz Ángela, Jaramillo Lina Eugenia, Cabrera Edgar VladimirAbstract:The Erdheim-Chester’s disease is extremely rare in children. We present the case of a 12-year-old girl with histological and radiological diagnosis of this disease and mutation of the BRAF Gene, who developed multisystemic compromise requiring treatment with daBRAFenib.We identified 22 reports of this condition among children worldwide and this is the second pediatric case in Latin America. Diagnostic imaging is critical to confirm Erdheim-Chester disease and for the surgical planning of the biopsy. Additionally, we identified the parasellar dark sign, which has previously been reported on lymphocytic hypophysitis.This report contributes to the current practice as it shows the clinical presentation and the diagnostic workout of this disease in pediatrics.La enfermedad de Erdheim-Chester es una condición extremadamente rara en la edad pediátrica. Se presenta el caso de una niña de 12 años con diagnóstico histológico y radiológico de enfermedad de Erdheim-Chester multisistémica y mutación en el gen BRAF, que requirió tratamiento con daBRAFenib.Hasta el momento, se han reportado 22 casos pediátricos en el mundo y este es el segundo en Latinoamérica. Se observó el hallazgo radiológico denominado signo oscuro paraselar, descrito hasta ahora en pacientes con hipofisitis autoinmunitaria para diferenciarlos de aquellos con adenomas hipofisarios.Este reporte contribuye a la literatura médica en dos aspectos fundamentales: las manifestaciones clínicas de la enfermedad y su diagnóstico en la población pediátrica
-
Enfermedad de Erdheim-Chester: primer caso pediátrico reportado en Colombia
'Instituto Nacional de Salud (Colombia)', 2021Co-Authors: Salazar, Luis Carlos, Moreno Luz Ángela, Jaramillo Lina Eugenia, Cabrera Edgar VladimirAbstract:Erdheim-Chester disease (ECD) is very infrequent in children. We present a 12-years-old girl, with histological and radiological diagnosis of Erdheim-Chester disease and mutation from BRAF Gene, who developed multisystemic compromise and required treatment with daBRAFenib. Currently, we identified 22 reports of this condition among children worldwide, this is the second pediatric case in Latin America. Diagnostic imaging is critical on confirming Erdheim-Chester disease as well as, surgical planning for biopsy. Also, the parasellar dark sign was identified, which has previously been reported on lymphocytic hypophysitis. This report contributes to current practice because it shows ECD’s clinical presentation and diagnostic workout in pediatrics.La enfermedad de Erdheim-Chester (EEC) es una entidad extremadamente rara en edad pediátrica. Se presenta el caso de una niña de 12 años, con diagnóstico histológico y radiológico de enfermedad de Erdheim-Chester multisistémica, mutación en el gen BRAF y adecuada respuesta al tratamiento con daBRAFenib. Hasta el momento se han reportado 22 casos pediátricos en el mundo y este es el segundo caso reportado en Latinoamérica. Se observó el hallazgo radiológico denominado signo oscuro paraselar o dark sign, hasta ahora, descrito en pacientes con hipofisitis autoinmune para diferenciarlos de aquellos con adenomas hipofisarios. Este reporte contribuye a la literatura médica en dos aspectos fundamentales: manifestaciones clínicas de la EEC y diagnóstico de la enfermedad en la población pediátrica
Yuchien Kao - One of the best experts on this subject based on the ideXlab platform.
-
recurrent BRAF Gene fusions in a subset of pediatric spindle cell sarcomas expanding the Genetic spectrum of tumors with overlapping features with infantile fibrosarcoma
The American Journal of Surgical Pathology, 2017Co-Authors: Yuchien Kao, Christopher D M Fletcher, Rita Alaggio, Leonard H Wexler, Lei Zhang, Yun Shao Sung, Dicle Orhan, Wei Chin Chang, David SwansonAbstract:Infantile fibrosarcomas (IFS) represent a distinct group of soft tissue tumors occurring in patients under two years of age and most commonly involving the extremities. Most IFS show recurrent ETV6-NTRK3 Gene fusions, sensitivity to chemotherapy, and an overall favorable clinical outcome. However, outside these well-defined pathologic features, no studies have investigated IFS lacking ETV6-NTRK3 fusions, or tumors with the morphology resembling IFS in older children. This study was triggered by the identification of a novel SEPT7-BRAF fusion in an unclassified retroperitoneal spindle cell sarcoma in a 16 year-old female by targeted RNA sequencing. FISH screening of nine additional tumors with similar phenotype and lacking ETV6-NTRK3 identified four additional cases with BRAF Gene rearrangements in the pelvic cavity (n=2), paraspinal region (n=1), and thigh (n=1) of young children (0–3 years old). Histologically, four cases including the index case shared a fascicular growth of packed monomorphic spindle cells, with uniform nuclei and fine chromatin, and a dilated branching vasculature; while the remaining case was composed of compact cellular sheets of short spindle to ovoid cells. In addition, a minor small blue round cell component was present in one case. Mitotic activity ranged from 1–9/10 high power fields. Immunohistochemical stains were non-specific, with only focal smooth muscle actin staining demonstrated in three cases tested. Of the remaining five BRAF negative cases, further RNA sequencing identified one case with EML4-NTRK3 in an 1 year-old boy with a foot IFS, and a second case with TPM3-NTRK1 fusion in a 7 week-old infant with a retroperitoneal lesion. Our findings of recurrent BRAF Gene rearrangements in tumors showing morphologic overlap with IFS expand the Genetic spectrum of fusion-positive spindle cell sarcomas, to include unusual presentations, such as older children and adolescents and predilection for axial location, thereby opening new opportunities for kinase-targeted therapeutic intervention.